...
cytk-img

Cytokinetics Inc, Common Stock

CYTK

NSQ

$46.36

-$1.42

(-2.97%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.64B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.57M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.78
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$36.24 L
$110.25 H
$46.36

About Cytokinetics Inc, Common Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCYTKSectorS&P500
1-Week Return-8.56%-2.06%-0.55%
1-Month Return-10.74%-1.92%2.72%
3-Month Return-17.13%-10.4%7.66%
6-Month Return-10.74%-4.6%10.15%
1-Year Return28.46%4.06%27.53%
3-Year Return17.37%1.94%32.31%
5-Year Return352.29%36.48%89.2%
10-Year Return848.06%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue26.87M55.83M70.43M94.59M7.53M[{"date":"2019-12-31","value":28.41,"profit":true},{"date":"2020-12-31","value":59.02,"profit":true},{"date":"2021-12-31","value":74.46,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.96,"profit":true}]
Cost of Revenue86.13M96.95M159.94M240.81M330.12M[{"date":"2019-12-31","value":26.09,"profit":true},{"date":"2020-12-31","value":29.37,"profit":true},{"date":"2021-12-31","value":48.45,"profit":true},{"date":"2022-12-31","value":72.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(59.26M)(41.12M)(89.51M)(146.22M)(322.59M)[{"date":"2019-12-31","value":-5925700000,"profit":false},{"date":"2020-12-31","value":-4112300000,"profit":false},{"date":"2021-12-31","value":-8951000000,"profit":false},{"date":"2022-12-31","value":-14622500000,"profit":false},{"date":"2023-12-31","value":-32259300000,"profit":false}]
Gross Margin(220.55%)(73.66%)(127.09%)(154.59%)(4284.10%)[{"date":"2019-12-31","value":-220.55,"profit":false},{"date":"2020-12-31","value":-73.66,"profit":false},{"date":"2021-12-31","value":-127.09,"profit":false},{"date":"2022-12-31","value":-154.59,"profit":false},{"date":"2023-12-31","value":-4284.1,"profit":false}]
Operating Expenses39.61M52.82M96.80M177.98M173.61M[{"date":"2019-12-31","value":22.26,"profit":true},{"date":"2020-12-31","value":29.68,"profit":true},{"date":"2021-12-31","value":54.39,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.55,"profit":true}]
Operating Income(98.87M)(93.94M)(186.31M)(324.20M)(496.20M)[{"date":"2019-12-31","value":-9886700000,"profit":false},{"date":"2020-12-31","value":-9394300000,"profit":false},{"date":"2021-12-31","value":-18631300000,"profit":false},{"date":"2022-12-31","value":-32420200000,"profit":false},{"date":"2023-12-31","value":-49620500000,"profit":false}]
Total Non-Operating Income/Expense(45.65M)(66.69M)(58.00M)(104.57M)(60.95M)[{"date":"2019-12-31","value":-4565000000,"profit":false},{"date":"2020-12-31","value":-6669400000,"profit":false},{"date":"2021-12-31","value":-5800200000,"profit":false},{"date":"2022-12-31","value":-10456700000,"profit":false},{"date":"2023-12-31","value":-6095000000,"profit":false}]
Pre-Tax Income(121.69M)(127.29M)(215.31M)(388.95M)(526.24M)[{"date":"2019-12-31","value":-12169200000,"profit":false},{"date":"2020-12-31","value":-12729000000,"profit":false},{"date":"2021-12-31","value":-21531400000,"profit":false},{"date":"2022-12-31","value":-38895500000,"profit":false},{"date":"2023-12-31","value":-52624400000,"profit":false}]
Income Taxes27.36M36.84M27.06M13.60M11.72M[{"date":"2019-12-31","value":74.26,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":73.43,"profit":true},{"date":"2022-12-31","value":36.9,"profit":true},{"date":"2023-12-31","value":31.82,"profit":true}]
Income After Taxes(149.05M)(164.13M)(242.37M)(402.55M)(537.97M)[{"date":"2019-12-31","value":-14905200000,"profit":false},{"date":"2020-12-31","value":-16413500000,"profit":false},{"date":"2021-12-31","value":-24237000000,"profit":false},{"date":"2022-12-31","value":-40255200000,"profit":false},{"date":"2023-12-31","value":-53796810500,"profit":false}]
Income From Continuous Operations(100.95M)(104.58M)(202.42M)(332.27M)(526.73M)[{"date":"2019-12-31","value":-10095500000,"profit":false},{"date":"2020-12-31","value":-10457700000,"profit":false},{"date":"2021-12-31","value":-20242200000,"profit":false},{"date":"2022-12-31","value":-33227400000,"profit":false},{"date":"2023-12-31","value":-52672800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(149.05M)(164.13M)(242.37M)(402.55M)(526.24M)[{"date":"2019-12-31","value":-14905200000,"profit":false},{"date":"2020-12-31","value":-16413500000,"profit":false},{"date":"2021-12-31","value":-24237000000,"profit":false},{"date":"2022-12-31","value":-40255200000,"profit":false},{"date":"2023-12-31","value":-52624400000,"profit":false}]
EPS (Diluted)(2.12)(2.01)(2.83)(4.22)(5.45)[{"date":"2019-12-31","value":-212,"profit":false},{"date":"2020-12-31","value":-201,"profit":false},{"date":"2021-12-31","value":-283,"profit":false},{"date":"2022-12-31","value":-422,"profit":false},{"date":"2023-12-31","value":-545,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CYTK
Cash Ratio 9.21
Current Ratio 9.28
Quick Ratio 9.28

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CYTK
ROA (LTM) -30.13%
ROE (LTM) -572.15%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CYTK
Debt Ratio Lower is generally better. Negative is bad. 1.01
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.01

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CYTK
Trailing PE NM
Forward PE NM
P/S (TTM) 1699.64
P/B 60.31
Price/FCF NM
EV/R 1682.71
EV/Ebitda NM
PEG NM

FAQs

What is Cytokinetics Inc share price today?

Cytokinetics Inc (CYTK) share price today is $46.36

Can Indians buy Cytokinetics Inc shares?

Yes, Indians can buy shares of Cytokinetics Inc (CYTK) on Vested. To buy Cytokinetics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CYTK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cytokinetics Inc be purchased?

Yes, you can purchase fractional shares of Cytokinetics Inc (CYTK) via the Vested app. You can start investing in Cytokinetics Inc (CYTK) with a minimum investment of $1.

How to invest in Cytokinetics Inc shares from India?

You can invest in shares of Cytokinetics Inc (CYTK) via Vested in three simple steps:

  • Click on Sign Up or Invest in CYTK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cytokinetics Inc shares
What is Cytokinetics Inc 52-week high and low stock price?

The 52-week high price of Cytokinetics Inc (CYTK) is $110.25. The 52-week low price of Cytokinetics Inc (CYTK) is $36.24.

What is Cytokinetics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cytokinetics Inc (CYTK) is

What is Cytokinetics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cytokinetics Inc (CYTK) is 60.31

What is Cytokinetics Inc dividend yield?

The dividend yield of Cytokinetics Inc (CYTK) is 0.00%

What is the Market Cap of Cytokinetics Inc?

The market capitalization of Cytokinetics Inc (CYTK) is $5.64B

What is Cytokinetics Inc’s stock symbol?

The stock symbol (or ticker) of Cytokinetics Inc is CYTK

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top